Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110δ
- 1 October 2020
- journal article
- letter
- Published by Elsevier in Clinical Immunology
- Vol. 219, 108543
Abstract
No abstract availableKeywords
Funding Information
- Università degli Studi di Brescia
This publication has 9 references indexed in Scilit:
- Activated PI3 Kinase Delta Syndrome: From Genetics to TherapyFrontiers in Immunology, 2018
- Epstein–Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) ImmunodeficiencyFrontiers in Immunology, 2018
- Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humansJournal of Allergy and Clinical Immunology, 2017
- Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1)Haematologica, 2017
- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyJournal of Allergy and Clinical Immunology, 2017
- 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic ArthritisAnnals of the Rheumatic Diseases, 2016
- Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway DamageScience, 2013
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiencyNature Immunology, 2013
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006